Chardan raised the firm’s price target on Ocugen to $5 from $4 and keeps a Buy rating on the shares post the Q4 report. The pivotal OCU400 study in retinitis pigmentosa is on track to initiate this month, the analyst tells investors in a research note. The firm points out Ocugen is exploring various options to raise additional capital, including debt financing and partnering its programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
- Ocugen announces dosing completion of Cohort 2 in OCU410 Phase 1/2 trial
- Ocugen files $175M mixed securities shelf
- Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
- Ocugen announces CHMP of EMA reviewed Phase 3 study design for OCU400
